blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4153161

EP4153161 - THE COMBINATION OF ACETYL LEUCINE AND 4-AMINOPYRIDINE OR ACETAZOLAMIDE FOR TREATING ATAXIA [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  24.02.2023
Database last updated on 03.09.2024
FormerThe international publication has been made
Status updated on  26.11.2021
Formerunknown
Status updated on  09.06.2021
Most recent event   Tooltip13.03.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
IntraBio Ltd
Summit House
170 Finchley Road
London NW3 6BP / GB
[2023/13]
Inventor(s)01 / STRUPP, Michael
81377 Munich / DE
 [2023/13]
Representative(s)Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[2023/13]
Application number, filing date21728642.620.05.2021
[2023/13]
WO2021IB54399
Priority number, dateUS202063028760P22.05.2020         Original published format: US 202063028760 P
[2023/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021234642
Date:25.11.2021
Language:EN
[2021/47]
Type: A1 Application with search report 
No.:EP4153161
Date:29.03.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 25.11.2021 takes the place of the publication of the European patent application.
[2023/13]
Search report(s)International search report - published on:EP25.11.2021
ClassificationIPC:A61K31/198, A61K31/433, A61K31/4409, A61P21/00, A61P25/00
[2023/13]
CPC:
A61P21/00 (EP,KR); A61K31/198 (EP,KR,US); A61K31/433 (EP,KR,US);
A61K31/4409 (EP,KR,US); A61P25/00 (EP,KR); A61P25/14 (US);
A61K2300/00 (KR) (-)
C-Set:
A61K31/198, A61K2300/00 (EP);
A61K31/433, A61K2300/00 (EP);
A61K31/4409, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/13]
TitleGerman:KOMBINATION VON ACETYLLEUCIN UND 4-AMINOPYRIDIN ODER ACETAZOLAMID ZUR BEHANDLUNG VON ATAXIE[2023/13]
English:THE COMBINATION OF ACETYL LEUCINE AND 4-AMINOPYRIDINE OR ACETAZOLAMIDE FOR TREATING ATAXIA[2023/13]
French:ASSOCIATION D'ACÉTYLLEUCINE ET DE 4-AMINOPYRIDINE OU D'ACÉTAZOLAMIDE POUR TRAITER L'ATAXIE[2023/13]
Entry into regional phase13.12.2022National basic fee paid 
13.12.2022Designation fee(s) paid 
13.12.2022Examination fee paid 
Examination procedure13.12.2022Examination requested  [2023/13]
13.12.2022Date on which the examining division has become responsible
17.07.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
13.12.2022Renewal fee patent year 03
13.03.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]  - ROMAN SCHNIEPP ET AL, "Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series", CEREBELLUM & ATAXIAS, (20160412), vol. 3, doi:10.1186/s40673-016-0046-2, page 8, XP055390569 [Y] 1-26 * page 1, column r, paragraph 1 - page 2, column r, paragraph 1 * * tables 1,2 *

DOI:   http://dx.doi.org/10.1186/s40673-016-0046-2
 [Y]  - FEIL KATHARINA ET AL, "Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus", CEREBELLUM, TAYLOR AND FRANCIS, GB, vol. 15, no. 1, doi:10.1007/S12311-015-0733-1, ISSN 1473-4222, (20151030), pages 38 - 42, (20151030), XP035783963 [Y] 1-26 * page 39, column l, paragraph l - column r, paragraph 1 * * page 40, column l, paragraphs 2-3 * * page 40, column r, paragraph 2 - page 41, column l, paragraph 1 * * table 1 *

DOI:   http://dx.doi.org/10.1007/s12311-015-0733-1
 [XP]  - PENKAVA JOSEF ET AL, "A novel pathogenicvariant causing episodic ataxia type 2 (EA2) spectrum phenotype in four family members and a novel combined therapy", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, (20201231), vol. 267, no. Suppl 1, doi:10.1007/S00415-020-10190-1, ISSN 0340-5354, pages 181 - 184, XP037311255 [XP] 1,2,4,5,7,11-19,21,23-26 * page S183, column l, paragraph 3 - column r, paragraph 1 * * page S182, column l, paragraph 2 *

DOI:   http://dx.doi.org/10.1007/s00415-020-10190-1
by applicantUS9283181
    - ASHIZAWAXIA, Continuum (Minneap Min, (20160000), vol. 22, pages 1208 - 1226
    - KIPFERSTRUPP, Movement Disorders Clinical Practice, (20140000), vol. 1, pages 285 - 290
    - "Episodic ataxias", JEN JCWAN J, Handbook of clinical neurology, (20180000), vol. 155, pages 205 - 215
    - IMBRICI PEUNSON LHGRAVES TDBHATIA KPWADIA NHKULLMANN DMHANNA MG, "Late-onset episodic ataxia type 2 due to an in-frame insertion in CACNA1A", Neurology, (20050000), vol. 65, no. 6, pages 944 - 946
    - JEN JKIM GWBALOH RW, "Clinical spectrum of episodic ataxia type 2", Neurology, (20040000), vol. 62, no. 1, pages 17 - 22
    - RIANT et al., Revue Neurologique, (20110000), vol. 7, no. 57, pages 401 - 407
    - OPHOFF RATERWINDT GMVERGOUWE MNVAN EIJK ROEFNER PJHOFFMAN SMLAMERDIN JEMOHRENWEISER HWBULMAN DEFERRARI M, "Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4", Cell, (19960000), vol. 87, no. 3, doi:10.1016/S0092-8674(00)81373-2, pages 543 - 552, XP000647699

DOI:   http://dx.doi.org/10.1016/S0092-8674(00)81373-2
    - ILG WBASTIAN AJBOESCH SBURCIU RGCELNIK PCLAASSEN JFEIL KKALLA RMIYAI INACHBAUER W, "Consensus paper: management of degenerative cerebellar disorders", Cerebellum (London, England, (20140000), vol. 13, no. 2, doi:10.1007/s12311-013-0531-6, pages 248 - 268, XP055588470

DOI:   http://dx.doi.org/10.1007/s12311-013-0531-6
    - GANDINI et al., J Neurol., (20200000), vol. 267, pages 1211 - 1220
    - PATEL et al., "Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain", CNS Drugs, (20170000), vol. 31, pages 109 - 133
    - KABANOV et al., "New Technologies for Drug Delivery across the Blood Brain Barrier", Curr Pharm Des., (20040000), vol. 10, no. 12, pages 1355 - 1363
    - CHENG et al., "Highly Stabilized Curcumin Nanoparticles Tested in an In Vitro Blood-Brain Barrier Model and in Alzheimer's Disease Tg2576 Mice", The AAPS Journal, (20130000), vol. 15, no. 2, doi:10.1208/s12248-012-9444-4, pages 324 - 336, XP055624412

DOI:   http://dx.doi.org/10.1208/s12248-012-9444-4
    - LAHDE et al., "Production of L-Leucine Nanoparticles under Various Conditions Using an Aerosol Flow Reactor Method", Journal of Nanomaterials, (20080000), vol. 2008
    - HANSON et al., "Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease", BMC Neurosci., (20080000), vol. 9, no. 3, doi:10.1186/1471-2202-9-S3-S5, page S5, XP021042511

DOI:   http://dx.doi.org/10.1186/1471-2202-9-S3-S5
    - SINTAS et al., Sci Rep, (20170000), vol. 7, page 2514
    - KIM et al., J Clin Neurol, (20060000), vol. 2, pages 268 - 271
    - DENIER et al., Neurology, (19990000), vol. 52, pages 1816 - 1821
    - CHOICHOI, JMov Disord, (20160000), vol. 9, pages 129 - 135
    - ANGELINI et al., European Journal of Medical Genetics, (20190000), vol. 62, page 103530
    - GRIGGS RCMOXLEY RT, 3RDLAFRANCE RAMCQUILLEN J, "Hereditary paroxysmal ataxia: response to acetazolamide", Neurology, (19780000), vol. 28, no. 12, pages 1259 - 1264
    - KIPFER SSTRUPP M, "The Clinical Spectrum of Autosomal-Dominant Episodic Ataxias", Movement disorders clinical practice, (20140000), vol. 1, no. 4, pages 285 - 290
    - RIANT FVAHEDI KTOURNIER-LASSERVE E, "Hereditary episodic ataxia", Revue neurologique, (20110000), vol. 167, no. 5, pages 401 - 407
    - JEN JCGRAVES TDHESS EJHANNA MGGRIGGS RCBALOH RW, "Primary episodic ataxias: diagnosis, pathogenesis and treatment", Brain, (20070000), vol. 130, pages 2484 - 2493
    - ISAACS DABRADSHAW MJBROWN KHEDERA P, "Case report of novel CACNA1A gene mutation causing episodic ataxia type 2", SAGE open medical case reports, (20170000), vol. 5, page 2050313x17706044
    - GUTERMAN ELYURGIONAS BNELSON AB, "Pearls & Oy-sters: Episodic ataxia type 2: Case report and review of the literature", Neurology, (20160000), vol. 86, no. 23, pages e239 - 241
    - RICHARDS SAZIZ NBALE SBICK DDAS SGASTIER-FOSTER JGRODY WWHEGDE MLYON ESPECTOR E, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, (20150000), vol. 17, no. 5, pages 405 - 424
    - MANTUANO EROMANO SVENEZIANO LGELLERA CCASTELLOTTI BCAIMI STESTA DESTIENNE MZORZI GBUGIANI M, "Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2", Journal of the neurological sciences, (20100000), vol. 291, no. 1-2, doi:10.1016/j.jns.2010.01.010, pages 30 - 36, XP026934077

DOI:   http://dx.doi.org/10.1016/j.jns.2010.01.010
    - MAKSEMOUS NROY BSMITH RAGRIFFITHS LR, "Next-generation sequencing identifies novel CACNA1A gene mutations in episodic ataxia type 2", Molecular genetics & genomic medicine, (20160000), vol. 4, no. 2, pages 211 - 222
    - ANGELINI CVAN GILS JBIGOURDAN AJOUK PSLACOMBE DMENEGON PMOUTTON SRIANT FSOLE GTOURNIER-LASSERVE E, "Major intra-familial phenotypic heterogeneity and incomplete penetrance due to a CACNA1A pathogenic variant", European journal of medical genetics, (20190000), vol. 62, no. 6, page 103530
    - STRUPP MKALLA RDICHGANS MFREILINGER TGLASAUER SBRANDT T, "Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine", Neurology, (20040000), vol. 62, no. 9, pages 1623 - 1625
    - STRUPP MKALLA RCLAASSEN JADRION CMANSMANN UKLOPSTOCK TFREILINGER TNEUGEBAUER HSPIEGEL RDICHGANS M, "A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias", Neurology, (20110000), vol. 77, no. 3, pages 269 - 275
    - KALLA RSTRUPP M, "Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders", Current neuropharmacology, (20190000), vol. 17, no. 1, pages 7 - 13
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.